391 related articles for article (PubMed ID: 27083495)
21. Reimbursement and adoption of advanced therapies: the 5-C framework.
Malik NN
Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
[No Abstract] [Full Text] [Related]
22. Stem Cell and Regenerative Medicine Global Conference (SCRGC) 2016 (August 23-24, 2016 - Gyeonggi-do, Korea).
Vertès A
Drugs Today (Barc); 2016 Oct; 52(10):577-583. PubMed ID: 27910966
[TBL] [Abstract][Full Text] [Related]
23. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
24. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
Okada K; Miyata T; Sawa Y
Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
[TBL] [Abstract][Full Text] [Related]
25. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
26. Outstanding regulatory aspects in the European pharmaceutical market.
Kanavos P; Mossialos E
Pharmacoeconomics; 1999 Jun; 15(6):519-33. PubMed ID: 10538326
[TBL] [Abstract][Full Text] [Related]
27. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
28. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
29. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries.
Atikeler EK; Özçelikay G
Springerplus; 2016; 5(1):1876. PubMed ID: 27833835
[TBL] [Abstract][Full Text] [Related]
31. Access and reimbursement pathways for digital health solutions and
Mantovani A; Leopaldi C; Nighswander CM; Di Bidino R
Front Med Technol; 2023; 5():1101476. PubMed ID: 36891483
[TBL] [Abstract][Full Text] [Related]
32. An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact.
Hills A; Awigena-Cook J; Genenz K; Ostertag M; Butler S; Eggimann AV; Hubert A
Cytotherapy; 2020 Dec; 22(12):772-779.e1. PubMed ID: 33046395
[TBL] [Abstract][Full Text] [Related]
33. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Tafuri G; Bracco A; Grueger J
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
[TBL] [Abstract][Full Text] [Related]
34. The social management of biomedical novelty: Facilitating translation in regenerative medicine.
Gardner J; Webster A
Soc Sci Med; 2016 May; 156():90-7. PubMed ID: 27019143
[TBL] [Abstract][Full Text] [Related]
35. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe.
Wurcel V; Perche O; Lesteven D; Williams DA; Schäfer B; Hopley C; Jungwirth R; Postulka A; Pasmans R; Hermansson LL; Ott M; Glorioso V
Public Health Genomics; 2016; 19(3):137-43. PubMed ID: 27237134
[TBL] [Abstract][Full Text] [Related]
36. Creating conditions for the success of the French industrial advanced therapy sector.
Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
[TBL] [Abstract][Full Text] [Related]
37. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
38. Patient access to pharmaceuticals: an international comparison.
Cohen J; Faden L; Predaris S; Young B
Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
[TBL] [Abstract][Full Text] [Related]
39. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
[TBL] [Abstract][Full Text] [Related]
40. Pediatric Market Access: A Qualitative Study.
Maas L; Joos A; Hiligsmann M
Ther Innov Regul Sci; 2024 Mar; 58(2):336-346. PubMed ID: 38172379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
